AI news ·
Carta Healthcare Secures $18.25M Series B1 to Advance AI-Driven Clinical Data Abstraction and Trial Matching
Carta Healthcare raised $18.25M in Series B1 funding led by UPMC Enterprises to advance AI-driven clinical data abstraction. The investment supports scaling and improving patient trial matching.
Carta Healthcare Secures $18.25 Million Series B1 Funding to Advance Clinical Data Abstraction
Carta Healthcare, a leader in AI-driven clinical data abstraction, has raised $18.25 million in Series B1 financing. The round was led by UPMC Enterprises, with strategic investments from MemorialCare Innovation Fund, Rex Health Ventures, Tampa General Hospital Ventures, and continued support from existing investors including Memorial Hermann Health System and Mass General Brigham Ventures.
Funding Purpose and Growth Plans
The fresh capital will help Carta Healthcare meet growing demand from health systems and life sciences companies seeking AI-powered solutions to transform clinical data into actionable insights. Following its late 2024 acquisition of Realyze Intelligence from UPMC Enterprises, Carta aims to expand its customer base, particularly within life sciences.
Realyze Intelligence’s AI technology rapidly analyzes both structured and unstructured data to identify patients eligible for clinical trials and research studies, enhancing patient trial matching capabilities.
About Carta Healthcare
Founded in 2017, Carta Healthcare combines artificial intelligence, machine learning, and clinical expertise to automate clinical data collection and analysis. This helps healthcare organizations generate high-quality data that supports quality improvement and operational efficiency.
Key Perspectives from Industry Leaders
- Brent Burns, UPMC Enterprises: “Health systems face significant challenges with clinical data abstraction and patient trial matching, which are time-consuming and labor-intensive. Carta Healthcare uses AI to streamline these processes and provide clinicians with valuable analytics to enhance patient care.”
- Navid Farzad, Frist Cressey Ventures: “Better clinical data abstraction is essential for improving healthcare. Carta’s AI platform automates data abstraction, delivering high-quality clinical data with an immediate return on investment by lowering labor costs.”
- Feby Abraham, Memorial Hermann Health System: “As a community-focused health system, investing in digital technologies like Carta Healthcare enables us to meet diverse patient needs and support our providers. This partnership helps us drive innovation and improve care quality.”
- Brent Dover, CEO of Carta Healthcare: “This investment validates our mission to equip care teams and researchers with timely, accurate data. It allows us to scale operations, deepen clinical expertise, and activate data in near real-time to support quality initiatives.”
- Lucas Tanner, CFO of Carta Healthcare: “Consistent year-over-year growth reflects our focus on delivering measurable value. The new funding strengthens our team and infrastructure to meet rising market demand and capture significant opportunities ahead.”
Carta Healthcare’s progress highlights the increasing role of AI in streamlining clinical data processes and supporting healthcare innovation. For professionals interested in AI applications in healthcare, exploring relevant training and resources can provide valuable insights into these emerging technologies.
To learn more about AI in healthcare, visit Complete AI Training Automation Courses.